• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

AstraZeneca's phase 3 heart disease trial hits, teeing up Pfizer showdown in Japan

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 02, 2024 at 12:12: PM
via AstraZeneca has the data to mount an attack on Pfizer’s dominance of a heart disease market. Friday, the Anglo-Swedish drugmaker reported positive top-line results from a phase 3 trial of acoramidis in Japan, teeing it up to file for regulatory approval in the country.

article source
 

<



Similar threads

cafead
AstraZeneca execs &#039;not worried&#039; after IL-33 drug fails to improve COPD breathing in phase 2
Replies
0
Views
38
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche races to regulators after matching AstraZeneca&#039;s rare disease blockbuster in phase 3
Replies
0
Views
199
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca&#039;s COVID-19 therapy hits goal in phase 3, but efficacy falls short of rivals
Replies
0
Views
249
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Amgen, AstraZeneca&#039;s tezepelumab hits goal in asthma phase 3
Replies
0
Views
358
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca&#039;s COVID-19 vaccine enters phase 2/3 clinical trial
Replies
0
Views
154
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote